AR073254A1 - Analogos de piridona y piridazona como moduladores de gpr119 - Google Patents
Analogos de piridona y piridazona como moduladores de gpr119Info
- Publication number
- AR073254A1 AR073254A1 ARP090102687A ARP090102687A AR073254A1 AR 073254 A1 AR073254 A1 AR 073254A1 AR P090102687 A ARP090102687 A AR P090102687A AR P090102687 A ARP090102687 A AR P090102687A AR 073254 A1 AR073254 A1 AR 073254A1
- Authority
- AR
- Argentina
- Prior art keywords
- aryl
- heteroaryl
- alkyl
- heterocyclyl
- nr14r14
- Prior art date
Links
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 title abstract 2
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 title abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 26
- 125000001072 heteroaryl group Chemical group 0.000 abstract 23
- 125000000217 alkyl group Chemical group 0.000 abstract 21
- 125000000623 heterocyclic group Chemical group 0.000 abstract 19
- 125000003342 alkenyl group Chemical group 0.000 abstract 16
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 16
- 125000000304 alkynyl group Chemical group 0.000 abstract 15
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 12
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 12
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 9
- 239000001257 hydrogen Substances 0.000 abstract 9
- 150000002431 hydrogen Chemical group 0.000 abstract 8
- 125000005843 halogen group Chemical group 0.000 abstract 7
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000001188 haloalkyl group Chemical group 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8106908P | 2008-07-16 | 2008-07-16 | |
| US8106008P | 2008-07-16 | 2008-07-16 | |
| US8105808P | 2008-07-16 | 2008-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073254A1 true AR073254A1 (es) | 2010-10-28 |
Family
ID=41137417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102687A AR073254A1 (es) | 2008-07-16 | 2009-07-15 | Analogos de piridona y piridazona como moduladores de gpr119 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8372837B2 (en:Method) |
| EP (1) | EP2313395B1 (en:Method) |
| JP (1) | JP2011528362A (en:Method) |
| CN (1) | CN102159566A (en:Method) |
| AR (1) | AR073254A1 (en:Method) |
| BR (1) | BRPI0915918A2 (en:Method) |
| CA (1) | CA2730929A1 (en:Method) |
| CY (1) | CY1113715T1 (en:Method) |
| DK (1) | DK2313395T3 (en:Method) |
| EA (1) | EA018268B1 (en:Method) |
| ES (1) | ES2400587T3 (en:Method) |
| HR (1) | HRP20130120T1 (en:Method) |
| MX (1) | MX2011000394A (en:Method) |
| PL (1) | PL2313395T3 (en:Method) |
| PT (1) | PT2313395E (en:Method) |
| SI (1) | SI2313395T1 (en:Method) |
| SM (1) | SMT201300040B (en:Method) |
| TW (1) | TW201006821A (en:Method) |
| WO (1) | WO2010009183A1 (en:Method) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010012848A (es) | 2008-06-03 | 2011-03-01 | Intermune Inc | Compuestos y metodos para tratar trastornos inflamatorios y fibroticos. |
| AR077215A1 (es) | 2009-06-24 | 2011-08-10 | Boehringer Ingelheim Int | Derivados de piperidina, composiciones farmaceuticas y metodos relacionados con ellos |
| US8481731B2 (en) | 2009-06-24 | 2013-07-09 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical composition and methods relating thereto |
| WO2011030139A1 (en) | 2009-09-11 | 2011-03-17 | Astrazeneca Ab | 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators |
| WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
| US8415367B2 (en) | 2010-04-08 | 2013-04-09 | Bristol-Myers Squibb Company | Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators |
| WO2011140161A1 (en) | 2010-05-06 | 2011-11-10 | Bristol-Myers Squibb Company | Benzofuranyl analogues as gpr119 modulators |
| BR112012028445A2 (pt) | 2010-05-06 | 2016-07-19 | Bristol Myers Squibb Co | compostos de heteroarila bicíclica como moduladores de gpr119 |
| PH12012502255A1 (en) | 2010-05-17 | 2013-02-04 | Array Biopharma Inc | Piperidinyl-substituted lactams as gpr119 modulators |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| EP2625177B1 (en) | 2010-10-08 | 2015-07-29 | Cadila Healthcare Limited | Novel gpr 119 agonists |
| EP2718279B1 (en) | 2011-06-09 | 2016-08-10 | Rhizen Pharmaceuticals SA | Novel compounds as modulators of gpr-119 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2850073B1 (en) | 2012-05-16 | 2017-07-19 | Bristol-Myers Squibb Company | Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators |
| CA2878625A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| AU2013203000B9 (en) | 2012-08-10 | 2017-02-02 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| CN103664795B (zh) * | 2012-09-06 | 2017-10-03 | 华东理工大学 | 哒嗪酮类化合物及其用途 |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| US9499553B2 (en) | 2013-03-13 | 2016-11-22 | Chugai Seiyaku Kabushiki Kaisha | Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same |
| PT2975030T (pt) * | 2013-03-13 | 2020-09-28 | Chugai Pharmaceutical Co Ltd | Derivado de di-hidropiridazina-3,5-diona |
| AU2014255974B2 (en) | 2013-04-18 | 2018-02-22 | Climeworks Ag | Low-pressure drop structure of particle adsorbent bed for adsorption gas separation process |
| AU2014258128A1 (en) * | 2013-04-25 | 2015-10-29 | Yuhan Corporation | Novel triazolone derivatives or salts thereof and pharmaceutical composition comprising the same |
| CN106459042B (zh) | 2014-04-02 | 2019-06-28 | 英特穆恩公司 | 抗纤维化吡啶酮类 |
| CN104370806B (zh) * | 2014-06-17 | 2017-07-07 | 中国海洋大学 | 一种吡啶酮生物碱类化合物及其制备方法和用途 |
| IL277495B2 (en) * | 2018-03-23 | 2024-08-01 | Carmot Therapeutics Inc | Modulators of protein-coupled receptors - G |
| EP3919486B1 (en) * | 2018-04-25 | 2023-06-07 | Bayer Aktiengesellschaft | Novel heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides |
| EA202190847A1 (ru) * | 2018-09-27 | 2021-06-23 | Фмк Корпорейшн | Промежуточные продукты для получения гербицидных пиридазинонов |
| CN110845426A (zh) * | 2019-11-29 | 2020-02-28 | 都创(上海)医药科技有限公司 | 一种2-氯-5-氰基嘧啶化合物制备方法 |
| AU2021228729A1 (en) | 2020-02-28 | 2022-09-22 | Kallyope, Inc. | GPR40 agonists |
| WO2021231630A1 (en) * | 2020-05-13 | 2021-11-18 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| UY39222A (es) | 2020-05-19 | 2021-11-30 | Kallyope Inc | Activadores de la ampk |
| AU2021297323A1 (en) | 2020-06-26 | 2023-02-16 | Kallyope, Inc. | AMPK activators |
| CR20230530A (es) | 2021-05-13 | 2024-02-19 | Carmot Therapeutics Inc | Moduladores de los receptores acoplados a proteínas g. |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3826643A (en) | 1967-08-07 | 1974-07-30 | American Cyanamid Co | Method of controlling undesirable plant species using 3-nitropyridines |
| US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
| US5488064A (en) | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
| US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
| US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
| AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
| US6566384B1 (en) | 1996-08-07 | 2003-05-20 | Darwin Discovery Ltd. | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| UA57811C2 (uk) | 1997-11-21 | 2003-07-15 | Пфайзер Продактс Інк. | Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності |
| TR200100149T2 (tr) | 1998-07-06 | 2001-10-22 | Bristol-Myers Squibb Company | Dual anjiyotensin endotelin alıcı antagonistleri olarak bifenil-sülfonamitler |
| EP1140862A4 (en) | 1998-12-23 | 2004-07-28 | Bristol Myers Squibb Pharma Co | THROMBIN OR Xa FACTOR INHIBITORS |
| CA2413241A1 (en) | 2000-06-29 | 2002-01-10 | Bristol-Myers Squibb Pharma Company | Thrombin or factor xa inhibitors |
| DE60125227T2 (de) | 2000-12-01 | 2007-09-20 | Astellas Pharma Inc. | Verfahren zum screening von diabetes-heilverfahren |
| CA2469435A1 (en) | 2001-12-21 | 2003-07-24 | X-Ceptor Therapeutics, Inc. | Modulators of lxr |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| CA2488635C (en) * | 2002-06-12 | 2012-10-23 | Abbott Laboratories | Antagonists of melanin concentrating hormone receptor |
| AU2004205642C1 (en) | 2003-01-14 | 2012-01-12 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| KR20050106033A (ko) | 2003-02-24 | 2005-11-08 | 아레나 파마슈티칼스, 인크. | 글루코스 대사 조절제로서의 페닐- 및피리딜피페리딘-유도체 |
| SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| UA86943C2 (ru) * | 2003-07-11 | 2009-06-10 | Арена Фармасьютикалз, Инк. | Тризамещенные производные арилов и гетероарилов как модуляторы метаболизма и профилактика и лечение связанных с ними нарушений |
| BRPI0412689A (pt) | 2003-07-14 | 2006-10-03 | Arena Pharm Inc | derivados de heteroarila e arila fundida como moduladores de metabolismo e a profilaxia e tratamento de distúrbios relacionados a ele |
| SG144942A1 (en) * | 2003-07-14 | 2008-08-28 | Arena Pharm Inc | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| US20070088163A1 (en) | 2003-09-12 | 2007-04-19 | Kemia, Inc. | Modulators of calcitonin and amylin activity |
| US20080269114A1 (en) | 2004-03-17 | 2008-10-30 | 7Tm Pharma A/S | Y4 Selective Receptor Agonists For Thereapeutic Interventions |
| MXPA06012683A (es) | 2004-05-03 | 2007-01-16 | Hoffmann La Roche | Derivados de indolilo como moduladores de receptor x del higado. |
| WO2005121121A2 (en) * | 2004-06-04 | 2005-12-22 | Arena Pharmaceuticals, Inc. | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| WO2006067532A1 (en) | 2004-12-24 | 2006-06-29 | Prosidion Ltd | G-protein coupled receptor agonists |
| MY148521A (en) * | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| JP5349960B2 (ja) | 2005-06-23 | 2013-11-20 | エモリー ユニバーシティー | 腫瘍画像化のためのアミノ酸類似体の立体選択的合成 |
| WO2007003961A2 (en) * | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
| TW200738682A (en) * | 2005-12-08 | 2007-10-16 | Organon Nv | Isoquinoline derivatives |
| AR059898A1 (es) * | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| WO2008025799A1 (en) * | 2006-08-30 | 2008-03-06 | Biovitrum Ab (Publ) | Pyridazine compounds for treating gpr119 related disorders |
| EP2144902B1 (en) * | 2007-05-04 | 2012-05-16 | Bristol-Myers Squibb Company | [6,6]and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists |
| CA2693444A1 (en) * | 2007-07-17 | 2009-01-22 | Bristol-Myers Squibb Company | Method for modulating gpr119 g protein-coupled receptor and selected compounds |
| JPWO2010074090A1 (ja) * | 2008-12-25 | 2012-06-21 | 日産化学工業株式会社 | ピリダジン−３（２ｈ）−オン化合物塩酸塩の結晶及びその製造方法 |
| US8415367B2 (en) * | 2010-04-08 | 2013-04-09 | Bristol-Myers Squibb Company | Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators |
-
2009
- 2009-07-10 TW TW098123477A patent/TW201006821A/zh unknown
- 2009-07-15 DK DK09790426.2T patent/DK2313395T3/da active
- 2009-07-15 AR ARP090102687A patent/AR073254A1/es not_active Application Discontinuation
- 2009-07-15 PL PL09790426T patent/PL2313395T3/pl unknown
- 2009-07-15 HR HRP20130120AT patent/HRP20130120T1/hr unknown
- 2009-07-15 EA EA201100210A patent/EA018268B1/ru not_active IP Right Cessation
- 2009-07-15 BR BRPI0915918A patent/BRPI0915918A2/pt not_active IP Right Cessation
- 2009-07-15 US US13/003,914 patent/US8372837B2/en active Active
- 2009-07-15 WO PCT/US2009/050618 patent/WO2010009183A1/en not_active Ceased
- 2009-07-15 PT PT97904262T patent/PT2313395E/pt unknown
- 2009-07-15 ES ES09790426T patent/ES2400587T3/es active Active
- 2009-07-15 SI SI200930537T patent/SI2313395T1/sl unknown
- 2009-07-15 EP EP09790426A patent/EP2313395B1/en not_active Not-in-force
- 2009-07-15 CN CN2009801362083A patent/CN102159566A/zh active Pending
- 2009-07-15 JP JP2011518862A patent/JP2011528362A/ja active Pending
- 2009-07-15 CA CA2730929A patent/CA2730929A1/en not_active Abandoned
- 2009-07-15 MX MX2011000394A patent/MX2011000394A/es active IP Right Grant
-
2013
- 2013-01-18 US US13/744,604 patent/US20130131074A1/en not_active Abandoned
- 2013-02-22 CY CY20131100168T patent/CY1113715T1/el unknown
- 2013-04-03 SM SM201300040T patent/SMT201300040B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2313395T3 (pl) | 2013-05-31 |
| SMT201300040B (it) | 2013-05-06 |
| SI2313395T1 (sl) | 2013-04-30 |
| WO2010009183A1 (en) | 2010-01-21 |
| JP2011528362A (ja) | 2011-11-17 |
| TW201006821A (en) | 2010-02-16 |
| EA018268B1 (ru) | 2013-06-28 |
| EP2313395B1 (en) | 2012-12-19 |
| US20130131074A1 (en) | 2013-05-23 |
| ES2400587T3 (es) | 2013-04-10 |
| EA201100210A1 (ru) | 2011-08-30 |
| BRPI0915918A2 (pt) | 2018-07-10 |
| US8372837B2 (en) | 2013-02-12 |
| US20110263548A1 (en) | 2011-10-27 |
| PT2313395E (pt) | 2013-03-07 |
| CA2730929A1 (en) | 2010-01-21 |
| EP2313395A1 (en) | 2011-04-27 |
| MX2011000394A (es) | 2011-03-01 |
| CY1113715T1 (el) | 2016-06-22 |
| CN102159566A (zh) | 2011-08-17 |
| HRP20130120T1 (hr) | 2013-03-31 |
| DK2313395T3 (da) | 2013-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073254A1 (es) | Analogos de piridona y piridazona como moduladores de gpr119 | |
| ES2371515T3 (es) | Agonistas del receptor grp119 acoplado a proteína g. piridona. | |
| AR065322A1 (es) | 2-aminooxazolinas comoligandos de taar1 | |
| AR071361A1 (es) | Metodo para preparar 3-t rifluorometil chalconas | |
| ES2770058T3 (es) | Compuestos y composiciones destinados a modular las actividades de quinasa de EGFR mutante | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
| AR066438A1 (es) | Compuestos nitrogenados condensados, composiciones farmaceuticas que los contienen y usos de las mismas para el tratamiento de diabetes, obesidad y enfermedades asociadas a ellas. | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| PE20120027A1 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes | |
| AR068466A1 (es) | Cianoisoquinolina | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| AR075050A1 (es) | Dicianopiridinas alquilamino-sustituidas | |
| AR083694A1 (es) | USO DE COMPUESTOS FARMACEUTICOS ACTIVOS PARA EL TRATAMIENTO DE ESTADOS PATOLOGICOS DEL SISTEMA NERVIOSO CENTRAL, COMPOSICION FARMACEUTICA, MODULADOR ALOSTERICO NEGATIVO DEL GABA A a5, METODO | |
| CO2018000795A2 (es) | Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il)propanoico sustituido | |
| PE20190504A1 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
| PE20141556A1 (es) | Derivados de etinilo como moduladores alostericos de mglur5 | |
| AR072538A1 (es) | Derivados de indolinonas, composiciones farmacéuticas y usos | |
| ECSP13012980A (es) | Derivados de fenil- o piridinil-etinilo | |
| PE20090548A1 (es) | Compuestos aza-biciclohexano como inhibidores de trombina | |
| DOP2015000132A (es) | Moduladores selectivos del receptor de andrógenos novedosos | |
| PE20190964A1 (es) | Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica | |
| PE20170427A1 (es) | Peptidos como agonistas de la oxitocina | |
| PE20050293A1 (es) | Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos | |
| AR074467A1 (es) | Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |